Hayek Kallen Investment Management Sells 4,478 Shares of Zoetis Inc. $ZTS

Key Points

• Hayek Kallen Investment Management reduced its stake in Zoetis Inc. by 57.8%, selling 4,478 shares, and now holds 3,263 shares valued at $537,000.
• Vanguard Group raised its holdings in Zoetis by 0.5%, increasing its share ownership to 41,556,164, while other investors like Polen Capital Management and Goldman Sachs also increased their positions in the company.
• Zoetis beat analysts' expectations with an EPS of $1.76 for the last quarter, surpassing estimates of $1.62, and reported a revenue of $2.46 billion, reflecting a 4.2% year-over-year increase.

Hayek Kallen Investment Management trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 57.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,263 shares of the company's stock after selling 4,478 shares during the period. Hayek Kallen Investment Management's holdings in Zoetis were worth $537,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock valued at $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC raised its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Northern Trust Corp raised its position in shares of Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after buying an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after buying an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. raised its position in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after buying an additional 312,746 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.18% of the company's stock.

Zoetis Trading Up 1.1%

Shares of ZTS opened at $156.45 on Friday. The firm's 50-day moving average price is $153.51 and its 200-day moving average price is $158.02. The firm has a market capitalization of $69.34 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 2.48 and a beta of 0.88. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZTS. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and an average price target of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.